Kathleen M. Mahoney

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma

David A. Braun, Kelly Street, Kelly P. Burke et al. · Cancer Cell · 2021 · 483 citations · Full text

Progressive Immune Dysfunction, Urology, Cancer Immunosurveillance +12

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

Jun Zhou, Kathleen M. Mahoney, Anita Giobbie‐Hurder et al. · Cancer Immunology Research · 2017 · 356 citations · Full text

Prognostic and predictive markers for the new immunotherapies.

Kathleen M. Mahoney, Michael B. Atkins · PubMed · 2014 · 139 citations

New Immunotherapies, Cancer Immunosurveillance, Pd-l1 Expression +15

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

Kathleen M. Mahoney, Sachet A. Shukla, Nikolaos Patsoukis et al. · Cancer Immunology Immunotherapy · 2018 · 134 citations · Full text

Tumor Biology, Molecular Immunology, Cancer Immunosurveillance +15

PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells

Kathleen M. Mahoney, Heather H. Sun, Xiaoyun Liao et al. · Cancer Immunology Research · 2015 · 126 citations · Full text

Immunocytochemical Technique, Immunology, Pathology +18